BioSpace News Archive

£16 million Series A led by Omega Funds, to advance disease-modifying oral medicines for debilitating chronic neurodegenerative disorders through IND-enabling studies

The global acute repetitive seizures market size is projected to hit around US$ 18.5 billion by 2030 and register a compound annual growth rate (CAGR) of about 46.7% from 2022 to 2030.

According to Precedence Research, the global biomarkers market is expected to grow from its estimated value of USD 63.06 billion in 2021 to USD 207.46 billion by the end of 2030. This represents an excellent CAGR of 14.1% from 2021 to 2030.

The global genomics market was estimated at USD 21.06 billion in 2021 and is expected to surpass USD 72.13 billion by 2030, growing at a CAGR of 13.65% between 2021 and 2030.

Hoth Therapeutics, Inc. announced that it received written notice from the NASDAQ Stock Market LLC on November 9, 2022, informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550 for continued listing on the NASDAQ Capital Market.

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that it will be presenting a poster on November 11 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

Odyssey Therapeutics, Inc. today announced the appointment of Jeff Hermes, Ph.D., as Executive Vice President of Enabling Sciences and promotion of Natalie Dales, Ph.D., to the newly created position of Chief of Research Operations and Portfolio Strategy.

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at the Wolfe Research Healthcare Conference on Wednesday, November 16, 2022 in New York City.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30, 2022 and other corporate highlights.

Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 104,000 shares of its common stock to four employees outside Fusion’s 2020 Stock Option and Incentive Plan.